Marjorie Boissinot

Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Alexandre Theocharides, Marjorie Boissinot, François Girodon et al. · Blood · 2007 · 320 citations

Medicine, Hematology, Molecular Genetics +14

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

Éric Lippert, Marjorie Boissinot, Róbert Královics et al. · Blood · 2006 · 235 citations · Full text

Medicine, Genetics, Hematology +7

The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)

Marjorie Boissinot, Richard Garand, M. Hamidou et al. · Blood · 2006 · 65 citations

Medicine, Hematology, Molecular Genetics +13

Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature

Josie Hayes, Helene Thygesen, Charlotte Alicia Tumilson et al. · Molecular Oncology · 2014 · 63 citations · Full text

Medicine, Bioinformatics, Oncology +14

An immunological biomarker to predict MTX response in early RA

Frédérique Ponchel, Vincent Goëb, Rekha Parmar et al. · Annals of the Rheumatic Diseases · 2013 · 60 citations

Life Sciences, Clinical Sciences, Immunology +17